Strides Pharma Science Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Strides Pharma Science kazanç ve gelirin sırasıyla yıllık 27.8% ve 10.7% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 27.8% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 17.6% olacağı tahmin edilmektedir.

Anahtar bilgiler

27.8%

Kazanç büyüme oranı

27.8%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	17.6%
Gelir büyüme oranı	10.7%
Gelecekteki özkaynak getirisi	17.6%
Analist kapsamı	Low
Son güncelleme	30 Jan 2025

Gelecekteki son büyüme güncellemeleri

Recent updates

Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors

Nov 01

Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge

Oct 21

After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar

Aug 14

Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)

Apr 04

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Feb 29

Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story

Dec 23

We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt

Sep 26

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Jun 08

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 02

Is Strides Pharma Science (NSE:STAR) A Risky Investment?

Jun 25

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Dec 21

Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50

Jul 28

Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)

Apr 13

Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?

Mar 04

Kazanç ve Gelir Büyüme Tahminleri

NSEI:STAR - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	57,684	6,028	8,524	N/A	2
3/31/2026	50,836	4,912	7,739	N/A	3
3/31/2025	45,738	3,305	2,418	N/A	3
12/31/2024	45,794	3,424	N/A	N/A	N/A
9/30/2024	44,103	1,771	6,344	8,172	N/A
6/30/2024	42,086	-475	N/A	N/A	N/A
3/31/2024	40,511	-1,248	5,829	7,011	N/A
12/31/2023	39,535	-1,525	N/A	N/A	N/A
9/30/2023	37,806	-2,280	3,043	3,903	N/A
6/30/2023	36,783	-924	N/A	N/A	N/A
3/31/2023	36,884	-2,212	-505	444	N/A
12/31/2022	35,680	-1,824	N/A	N/A	N/A
9/30/2022	34,976	-2,241	-2,101	-1,144	N/A
6/30/2022	33,220	-3,909	N/A	N/A	N/A
3/31/2022	30,703	-4,602	-4,012	-2,578	N/A
12/31/2021	31,127	-4,425	N/A	N/A	N/A
9/30/2021	31,504	-2,830	-1,188	1,572	N/A
6/30/2021	32,224	-543	N/A	N/A	N/A
3/31/2021	33,159	2,545	1,840	4,814	N/A
12/31/2020	30,260	28	N/A	N/A	N/A
9/30/2020	29,264	589	970	2,699	N/A
6/30/2020	28,480	1,266	N/A	N/A	N/A
3/31/2020	27,520	492	548	2,048	N/A
12/31/2019	35,828	2,859	N/A	N/A	N/A
9/30/2019	34,203	2,169	-1,519	1,896	N/A
6/30/2019	32,248	745	N/A	N/A	N/A
3/31/2019	21,784	840	-2,690	601	N/A
12/31/2018	28,547	-93	N/A	N/A	N/A
9/30/2018	28,090	139	N/A	N/A	N/A
6/30/2018	28,451	415	N/A	N/A	N/A
3/31/2018	28,451	544	N/A	1,871	N/A
12/31/2017	35,810	1,050	N/A	N/A	N/A
9/30/2017	36,593	1,124	N/A	N/A	N/A
6/30/2017	35,357	1,712	N/A	N/A	N/A
3/31/2017	27,554	2,335	N/A	2,881	N/A
12/31/2016	37,237	2,840	N/A	N/A	N/A
9/30/2016	36,573	2,410	N/A	N/A	N/A
6/30/2016	34,189	2,168	N/A	N/A	N/A
3/31/2016	28,622	1,317	N/A	732	N/A
12/31/2015	24,901	1,152	N/A	N/A	N/A
9/30/2015	12,962	860	N/A	N/A	N/A
6/30/2015	12,105	244	N/A	N/A	N/A
3/31/2015	11,958	16	N/A	834	N/A
3/31/2014	10,728	-1,867	N/A	-2,173	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: STAR 'nin tahmini kazanç büyümesi (yıllık 27.8% ) tasarruf oranının ( 6.7% ) üzerindedir.

Kazançlar ve Piyasa: STAR şirketinin kazançlarının (yıllık 27.8% ) Indian pazarından (yıllık 18.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: STAR şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: STAR şirketinin gelirinin (yıllık 10.7% ) Indian pazarından (yıllık 11% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: STAR şirketinin gelirinin (yıllık 10.7% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: STAR 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 17.6 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/02/07 15:30
Gün Sonu Hisse Fiyatı	2025/02/07 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Strides Pharma Science Limited 20 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Aditya Khemka	Ambit Capital
Harith Ahamed	Avendus Spark
Prakash Agarwal	Axis Capital Limited

Strides Pharma Science Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates increase by 15%

Price target decreased by 13% to ₹1,486

Price target increased by 20% to ₹994

Forecast breakeven date pushed back to 2025

Price target increased by 10% to ₹730

Price target increased by 10% to ₹530

Recent updates

Consensus EPS estimates increase by 15%

Third quarter 2025 earnings released: EPS: ₹9.56 (vs ₹0.49 loss in 3Q 2024)

Strides Pharma Science Limited Announces Re-Designation of Arun Kumar from Executive Chairperson to Non ­ Executive Chairperson Effective April 5, 2025

Strides Pharma Science Limited to Report Q3, 2025 Results on Jan 30, 2025

Price target decreased by 13% to ₹1,486

Strides Pharma Science Limited completed the Spin-Off of OneSource Specialty Pharma Limited.

New major risk - Share price stability

Now 59% undervalued after recent price drop

Strides Pharma Science Limited Announces Appointment of Dr. C Muthulingam as Executive Vice President - Research & Development

Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors

Second quarter 2025 earnings released: EPS: ₹10.14 (vs ₹14.54 loss in 2Q 2024)

Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge

Strides Pharma Science Limited to Report Q2, 2025 Results on Oct 24, 2024

Upcoming dividend of ₹2.50 per share

Strides Pharma Science Limited, Annual General Meeting, Sep 25, 2024

After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar

Strides Pharma Science Limited Announces Completion of Tenure of S Sridhar as Independent Director

First quarter 2025 earnings released: EPS: ₹7.64 (vs ₹0.79 loss in 1Q 2024)

Strides Pharma Science Limited to Report Q1, 2025 Results on Jul 29, 2024

Insufficient new directors

New minor risk - Dividend sustainability

Strides Pharma Science Limited Announces Chief Financial Officer Changes, Effective June 1, 2024

Price target increased by 20% to ₹994

Forecast breakeven date pushed back to 2025

Strides Pharma Science Limited to Report Q4, 2024 Results on May 22, 2024

Strides Pharma Science Limited Approves Appointment of Ameet P Hariani as Independent Director

Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Price target increased by 10% to ₹730

Third quarter 2024 earnings released: ₹0.49 loss per share (vs ₹8.86 loss in 3Q 2023)

Strides Pharma Science Limited to Report Q3, 2024 Results on Jan 30, 2024

Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story

Strides Pharma Global Pte. Limited Receives USFDA Approval for Generic Suprep®? Bowel Prep Kit

Now 21% undervalued

Strides Pharma Science Limited Announces Change in Management

Second quarter 2024 earnings released: ₹14.54 loss per share (vs ₹0.47 profit in 2Q 2023)

Strides Pharma Science Limited to Report Q2, 2024 Results on Oct 30, 2023

New major risk - Revenue and earnings growth

We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt

Strides Pharma Global Pte. Limited Receives Tentative United States Food & Drug Administration Approval for Dolutegravir Tablets

Strides Pharma Science Limited Announces Resignation of Ankit Gupta as Vice President and Head of Corporate Development and Strategy

Price target increased by 10% to ₹530

Upcoming dividend of ₹1.50 per share at 0.3% yield

Strides Pharma Science Limited to Report Q1, 2024 Results on Aug 02, 2023

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Strides Pharma Science Limited Recommends Dividend for Financial Year Ended March 31, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Strides Pharma Science Limited to Report Q4, 2023 Results on May 25, 2023

Price target decreased by 7.2% to ₹462

Third quarter 2023 earnings released: ₹8.86 loss per share (vs ₹13.55 loss in 3Q 2022)

Strides Pharma Science Limited to Report Q3, 2023 Results on Jan 24, 2023

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹2.54 (vs ₹18.12 loss in 2Q 2022)

Insufficient new directors

Strides Pharma Science Limited Announces Resignation of Director

Strides Pharma Science Limited to Report Q2, 2023 Results on Nov 14, 2022

Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022

Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

First quarter 2023 earnings released: ₹15.13 loss per share (vs ₹22.88 loss in 1Q 2022)

Strides Pharma Science Limited to Report Q1, 2023 Results on Jul 29, 2022

Is Strides Pharma Science (NSE:STAR) A Risky Investment?

Stelis Biopharma Limited and Strides Pharma Science Limited Receive the European Union Goods Manufacturing Practices (EU-GMP) Compliance Certificate

Now 20% undervalued after recent price drop

Strides Receives USFDA Approval for Ibuprofen Oral Suspension

Full year 2022 earnings: EPS misses analyst expectations

Strides Pharma Science Limited to Report Q4, 2022 Results on May 24, 2022

Price target decreased to ₹463

Insufficient new directors

Strides Pharma Science Limited Announces Re-Designation of Arun Kumar from Executive Chairperson to Non Executive Chairperson Effective April 5, 2025